A pan-cancer multi-omics atlas identifies HTR7 as a neuroimmune modulator associated with macrophage polarization and poor prognosis in AML

Abstract Serotonin signaling is increasingly implicated in cancer biology, but the role of 5-hydroxytryptamine receptor 7 (HTR7) in tumor growth and macrophage polarization remains poorly defined. We integrated pan-cancer multi-omics data from 33 TCGA tumor types with single-cell and spatial transcriptomics, functional assays, xenograft models, and computational drug screening, focusing on acute myeloid leukemia (AML). HTR7 was upregulated in multiple malignancies and preferentially enriched in monocyte/macrophage populations, with spatial expression overlapping macrophage-rich regions. In clear cell renal cell carcinoma, CellChat predicted TNF- and SPP1–integrin-mediated communication involving HTR7-positive macrophages. HTR7 depletion suppressed proliferation and migration in glioma, breast cancer, and hepatocellular carcinoma cells, reduced Vimentin and SNAI1 expression, and inhibited hepatocellular carcinoma and AML xenograft growth. In AML, elevated HTR7 expression was independently associated with shorter overall survival. HTR7 depletion reduced leukemic cell viability and induced G0/G1 arrest, while RNA sequencing revealed suppression of PI3K/AKT and cell-cycle programs. In primary human monocyte-derived macrophages and THP-1-derived macrophages, HTR7 knockdown impaired IL-4/IL-13-induced M2-like polarization and reduced M2-associated marker expression. In AML cell lines, HTR7 depletion reduced AKT and NF-κB phosphorylation and MRC1 and IL10 expression, whereas SC79 partially reversed these effects. Virtual screening and molecular dynamics simulations identified nilotinib as a candidate HTR7 ligand, and cellular thermal shift assays showed increased HTR7 thermal stability, consistent with intracellular target engagement. Higher HTR7 expression was associated with greater nilotinib sensitivity in BeatAML, whereas HTR7 depletion modestly increased nilotinib IC₅₀ values in AML cells. Together, these findings support HTR7 as a neuroimmune regulator of tumor growth and M2-like macrophage polarization, and as a candidate prognostic biomarker and therapeutic target in AML.

Authors

Institutions

Publication Details

Journal
Cell Death Discovery
Published
2026-11-16
DOI
https://doi.org/10.1038/s41420-026-03416-0
Primary Topic
Immune cells in cancer
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A pan-cancer multi-omics atlas identifies HTR7 as a neuroimmune modulator associated with macrophage polarization and poor prognosis in AML

Yansha Pan, Xiaoqin Xiong, Fengming Zhong, Xiaoqin Lei et al.
1 links
Cell Death Discovery
Immune cells in cancer
article

A pan-cancer multi-omics atlas identifies HTR7 as a neuroimmune modulator associated with macrophage polarization and poor prognosis in AML

Yansha Pan, Xiaoqin Xiong, Fengming Zhong, Xiaoqin Lei, Chenyu Jiang, Yuting Li, Qulian Guo, Xiumei Xu
article en

Abstract

Abstract Serotonin signaling is increasingly implicated in cancer biology, but the role of 5-hydroxytryptamine receptor 7 (HTR7) in tumor growth and macrophage polarization remains poorly defined. We integrated pan-cancer multi-omics data from 33 TCGA tumor types with single-cell and spatial transcriptomics, functional assays, xenograft models, and computational drug screening, focusing on acute myeloid leukemia (AML). HTR7 was upregulated in multiple malignancies and preferentially enriched in monocyte/macrophage populations, with spatial expression overlapping macrophage-rich regions. In clear cell renal cell carcinoma, CellChat predicted TNF- and SPP1–integrin-mediated communication involving HTR7-positive macrophages. HTR7 depletion suppressed proliferation and migration in glioma, breast cancer, and hepatocellular carcinoma cells, reduced Vimentin and SNAI1 expression, and inhibited hepatocellular carcinoma and AML xenograft growth. In AML, elevated HTR7 expression was independently associated with shorter overall survival. HTR7 depletion reduced leukemic cell viability and induced G0/G1 arrest, while RNA sequencing revealed suppression of PI3K/AKT and cell-cycle programs. In primary human monocyte-derived macrophages and THP-1-derived macrophages, HTR7 knockdown impaired IL-4/IL-13-induced M2-like polarization and reduced M2-associated marker expression. In AML cell lines, HTR7 depletion reduced AKT and NF-κB phosphorylation and MRC1 and IL10 expression, whereas SC79 partially reversed these effects. Virtual screening and molecular dynamics simulations identified nilotinib as a candidate HTR7 ligand, and cellular thermal shift assays showed increased HTR7 thermal stability, consistent with intracellular target engagement. Higher HTR7 expression was associated with greater nilotinib sensitivity in BeatAML, whereas HTR7 depletion modestly increased nilotinib IC₅₀ values in AML cells. Together, these findings support HTR7 as a neuroimmune regulator of tumor growth and M2-like macrophage polarization, and as a candidate prognostic biomarker and therapeutic target in AML.

Cell Death Discovery
Affiliated Hospital of Southwest Medical University (CN)
Department of Science and Technology of Sichuan Province, Southwest Medical University, Affiliated Hospital of Southwest Medical University
Good health and well-being
Immune cells in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon